Approval of the bluebird bio-partnered CAR-T is one part of a three-part, all-or-nothing wager between BMS and former shareholders in Celgene, which it acquired in a mega-merger last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback